Davenport & Co’s Theriva Biologics TOVX Stock Holding History

Davenport & Co’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	-$6K	–	719
2018 Q2	$6K	Hold	3	–	–	﹤0.01%	691
2018 Q1	$7.96K	Hold	3	–	–	﹤0.01%	686
2017 Q4	$12.7K	Buy	+3	New	+$18.7K	﹤0.01%	696

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Davenport & Co's TOVX Position: Q3 2018 in Review

Davenport & Co sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 3 shares — an estimated $6K sold.

Davenport & Co first reported a position in TOVX in Q4 2017 and held it in 3 quarters. The position peaked at $12.7K in Q4 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Davenport & Co reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Davenport & Co sold 3 Theriva Biologics shares in Q3 2018, an estimated $6K.
Davenport & Co first reported a position in Theriva Biologics in Q4 2017 and held it in 3 quarters.
Davenport & Co's Theriva Biologics position peaked at $12.7K in Q4 2017.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Davenport & Co's 13F filing for Q3 2018, filed 11 Oct 2018.